Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
Authors:
Open Access
- 10 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (10) , 864-873
Abstract
Background: The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV. Patients and Methods: We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients. Results: Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies. Conclusions: In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.Keywords
Funding Information
- Haas Family Foundation
- Millennium Pharmaceuticals Inc
- Takeda Pharmaceutical Company Ltd
- Seagen Inc (SGN35-IST-r001, SGN35-IST-030, SGN35-IST-002)
- National Cancer Institute (R21-CA74117)
- Anderson Cancer Center Core (CA16672-22)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24 CA 86815)
- Cutaneous T-Cell Lymphoma
- Patient Education and Research Fund
This publication has 38 references indexed in Scilit:
- CD30 expression in peripheral T-cell lymphomasHaematologica, 2013
- CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyBlood, 2013
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateClinical Cancer Research, 2010
- CD30 Expression and Proliferative Fraction in Nontransformed Mycosis FungoidesAmerican Journal of Surgical Pathology, 2009
- Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30Blood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine‐rich domains 2 and 5The FASEB Journal, 2004
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- Shedding of the soluble form of CD30 from the Hodgkin‐analogous cell line L540 is strongly inhibited by a new CD30‐specific antibody (Ki‐4)International Journal of Cancer, 1995
- Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stageBritish Journal of Haematology, 1990